_[Bevacizumab_Biosimilar_4].png "JAN: Japanese Accepted Names for Pharmaceuticals")
JAN: Japanese Accepted Names for Pharmaceuticals
A Rational Sequencing of Anti-Angiogenic Agents as Second-Line Treatment Choice for mCRC Patients Progressing After a Bevacizumab-Based First Line | Published in healthbook TIMES Oncology Hematology
_[Bevacizumab_Biosimilar_3].png "JAN: Japanese Accepted Names for Pharmaceuticals")
JAN: Japanese Accepted Names for Pharmaceuticals
Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology | Future Oncology
WO2017181021A1 - Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab - Google Patents
Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5+ colorectal cancer | Cell Death & Disease
Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
Immuno-priming durvalumab with bevacizumab in HER2-negative advanced breast cancer: a pilot clinical trial | Breast Cancer Research | Full Text
Sequential Treatment with Bevacizumab and Aflibercept for Metastatic Colorectal Cancer in Real-World Clinical Practice | SpringerLink
The multiple sequence alignment of known commercial antibodies s used... | Download Scientific Diagram
FOLFIRI plus cetuximab or bevacizumab for advanced colorectal cancer: final survival and per-protocol analysis of FIRE-3, a randomised clinical trial | British Journal of Cancer
IMGt Protein displays of the VH and V-KAPPA domains of the bevacizumab... | Download Scientific Diagram
Structure of Bevacizumab. The humanised Bevacizumab antibody consists... | Download Scientific Diagram
Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies | PNAS
Optimization of Heavy Chain and Light Chain Signal Peptides for High Level Expression of Therapeutic Antibodies in CHO Cells | PLOS ONE
Sci. Pharm. | Free Full-Text | A New Practice to Monitor the Fabrication Process of Fab-Targeting Ligands from Bevacizumab by LC-MS: Preparation and Analytical Characterization
Biomarkers to predict the clinical efficacy of bevacizumab in cancer - The Lancet Oncology
A Rational Sequencing of Anti-Angiogenic Agents as Second-Line Treatment Choice for mCRC Patients Progressing After a Bevacizumab-Based First Line | Published in healthbook TIMES Oncology Hematology
Structure-Function Studies of Two Synthetic Anti-vascular Endothelial Growth Factor Fabs and Comparison with the Avastin™ Fab - ScienceDirect
Biomolecules | Free Full-Text | The First WHO International Standard for Harmonizing the Biological Activity of Bevacizumab
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab | Eye
Frontiers | Quantification of Bevacizumab Activity Following Treatment of Patients With Ovarian Cancer or Glioblastoma
Rapid response of stage IV colorectal cancer with APC/TP53/KRAS mutations to FOLFIRI and Bevacizumab combination chemotherapy: a case report of use of liquid biopsy | BMC Medical Genetics | Full Text
Evaluating the Optimal Sequence of Treatment With EGFR Inhibitors and Bevacizumab in RAS Wild-Type Metastatic Colorectal Cancer
Amino acid sequence of variable heavy and light domains of RhumAb VEGF... | Download Scientific Diagram
Bevacizumab Antibody Affinity Maturation to Improve Ovarian Cancer Immunotherapy: In Silico Approach | SpringerLink
Amino acid sequence of variable heavy and light domains of RhumAb VEGF... | Download Scientific Diagram
